摘要
[目的]确定宣肺败毒颗粒在低温高湿环境下,A/PR/8/34(H1N1)流感病毒肺炎小鼠模型的治疗效果及作用机制。[方法]将ICR小鼠置于具有低温高湿环境的人工气候箱中,滴鼻给予流感病毒(A/PR/8/34)建立流感病毒肺炎模型。造模后第5天对小鼠每日给予宣肺败毒颗粒灌胃5 d,观察记录小鼠的行为学评分、体质量、脏器指数、肺部病毒载量、肺部影像学及形态学变化,蛋白印迹法检测炎症关键蛋白NF-κB的表达变化,流式细胞术检测宣肺败毒颗粒对小鼠免疫应答的调节。[结果]与模型组相比,宣肺败毒颗粒给药后小鼠表现出活跃程度上升、大便性状正常、肺部病毒载量降低、小鼠肺部炎性渗出减少,p-NF-κB P65表达降低,CD4+和CD8+T细胞百分比增高。[结论]宣肺败毒颗粒增加T细胞数量,减轻流感病毒肺炎小鼠的炎症反应。
[Objective] To establish a influenza virus(A/PR/8/34) pneumonia model under low temperature and high humidity,and evaluate the efficacy and mechanism of Xuanfei Baidu Granules(XFBD) against influenza.[Methods] ICR mice were placed in an artificial climate box with low temperature and high humidity,and influenza virus(A/PR/8/34) was given intranasally.On the 5th day after modeling,mice were given XFBD by gavage for 5 d.The behavioral score,body weight,organ index,pulmonary viral load,pulmonary imaging and morphological changes were observed and recorded.The expression of NF-κB,a key inflammatory protein,was detected by Western blot,and the regulation of XFBD on the immune response of mice was detected by flow cytometry.[Results] Compared with the model group,after administration of XFBD,mice showed increased activity,normal stool characteristics,decreased lung viral load,decreased inflammatory exudation in mice's lungs,decreased expression of p-NF-κB P65,and increased percentages of CD4~+ and CD8~+T cells.[Conclusion] XFBD increased the amount of T cells,and inhibited the inflammation of the influenza virus pneumonia under cold and high humidity conditions.
作者
袁也
马琳
赵倩茹
赵荣华
方青帝
王彧
YUAN Ye;MA Lin;ZHAO Qianru;ZHAO Ronghua;FANG Qingdi;WANG Yu(State Key Laboratory of Component-based Chinese Medicine,Tianjin University of Traditional Chinese Medicine,Tianjin 301617,China;School of Integrative Medicine,Tianjin University of Traditional Chinese Medicine,Tianjin 301617,China;Institute of Traditional Chinese Medicine,Tianjin University of Traditional Chinese Medicine,Tianjin 301617,China;China Academy of Chinese Medical Sciences,Beijing 100091,China;Tsinghua University,Beijing 100084,China)
出处
《天津中医药》
CAS
2024年第10期1309-1314,共6页
Tianjin Journal of Traditional Chinese Medicine
基金
国家重点研发计划(2021YFC1712903,2021YFE0200300)
组分中药国家重点实验室资助课题(CBCM2020103)
天津中医药大学中西医结合学院2021年研究生创新基金(ZXYCXLX202118)。